Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
Abstract: This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.
Type:
Grant
Filed:
January 22, 2018
Date of Patent:
September 3, 2019
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
David S. Eisenberg, Alice Soragni, Lin Jiang
Abstract: In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
August 27, 2019
Assignee:
The Trustees of the Stevens Institute of Technology
Abstract: The invention relates to a derivative of a GLP-1 analog of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, 38, or 39 of the GLP-1 analog. The side chain comprises a Branched linker, a 1st and a 2nd Protractor and a Pre-linker. The Branched linker is connected to the Lys residue of the GLP-1 analog via the Pre-linker and to the 1st and the 2nd Protractor via a 1st and 2nd Post-linker, respectively. The Branched linker may, e.g., be a tri-radical of Lys. The 1st and the 2nd Protractor is C20 diacid. Various linker elements may be used in the Prelinker as well as the two Post-linkers. The invention also relates to novel GLP-analogs, novel side chain intermediates and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogs and derivatives.
Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
Type:
Grant
Filed:
August 14, 2017
Date of Patent:
August 20, 2019
Assignee:
Lubris LLC
Inventors:
Edward R. Truitt, Nicole Barbara Justis Truitt
Abstract: Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
August 13, 2019
Assignee:
United-AH II, LLC
Inventors:
Stephen Kent Webel, Mark E. Swanson, Robert R. Kraeling, Michael E. Johnston
Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an a-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.
Abstract: The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
July 30, 2019
Assignee:
IMMUNOGEN, INC.
Inventors:
Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
Abstract: The invention is directed to a Ca2+ precipitable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipitable tags and cassettes.
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
July 23, 2019
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, ii) an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1, or iii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1.
Type:
Grant
Filed:
February 17, 2015
Date of Patent:
July 23, 2019
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)
Abstract: According to the embodiments described herein, a series of biological materials for treatment/therapy of DMD and/or BMD through the recovery of sarcolemmal nNOS is provided. The biological material comprises the complete dystrophin repeats R16 and R17 or certain domains, sections, or fragments of the dystrophin repeats R16 and R17. In some aspects, such domains, sections, or fragments may be selected from sequence motifs including dystrophin R17 ?1 helix, ?2 and ?3 helices of both R16 and R17, or a combination thereof.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
July 16, 2019
Assignee:
THE CURATORS OF THE UNIVERSITY OF MISSOURI
Inventors:
Yi Lai, Junling Zhao, Yongping Yue, Dongsheng Duan
Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
July 16, 2019
Assignee:
Cambridge Enterprise Limited
Inventors:
James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
Abstract: The present invention relates to analytical testing devices including micro-environment sensors and methods for assaying coagulation in a fluid sample applied to the micro-environment sensors, and in particular, performing one or more types of coagulation assays using one or more micro-environment sensors in a single point of care combined test cartridge. For example, the present invention may be directed to test sensor including at least one transducer coated with a polymer layer. The polymer layer comprises a thrombin-cleavable peptide with a detectable moiety.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
July 16, 2019
Assignee:
Abbott Point of Care Inc.
Inventors:
Tian-Xian Zhao, Anjulia Chiu-Yuk Wong, Glenn Brian Martin, Katrina Petronilla Di Tullio, Isabelle Louisette Thibodeau, Steven Roy Breeze, Smitha R K Sutrala, Eric Hong, Sheila Diane Ball
Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
July 16, 2019
Assignees:
USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.
Inventors:
Lenka Maletinska, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
Abstract: Described herein are methods for identifying signature peptides for quantifying a polypeptide of interest in a sample. The methods include cleaving the polypeptide into peptides; detecting a multiplicity of the peptides with a quantitative analytical instrument; comparing the linearity of signals attributable to pairs of the peptides in a multiplicity of samples; and selecting signature peptides from a group of peptides with more highly correlated signals.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
July 16, 2019
Assignees:
Cedars-Sinai Medical Center, The Johns Hopkins University
Inventors:
Eric Grote, Qin Fu, Jennifer Van Eyk, Vidya Venkatraman
Abstract: The present invention relates to a process for the preparation of Liraglutide, which comprises: a) synthesis of suitable fragments (protected) by solid phase peptide synthesis; b) coupling of the suitable fragments on solid support; c) concurrently cleaving the protected peptide from the solid support and de-protecting the peptide; d) purification of Liraglutide (crude) on reverse phase HPLC; e) isolating pure Liraglutide.
Type:
Grant
Filed:
October 31, 2015
Date of Patent:
July 9, 2019
Assignee:
Auro Peptides Ltd.
Inventors:
Suresh Kumar Vadlamani, Patil Nilesh Dagadu, Mohammed Abdul Shafee, Sanjay Devidas Patil, Nagana Goud Agasaladinni
Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
July 9, 2019
Assignee:
BIOM'UP
Inventors:
Christian Gagnieu, Patricia Forest, Sylvain Picot